NEPHROPLUS · NSE
Nephrocare Health Services Limited
₹743.35
+1.12% (+₹8.25)
Prev. close
₹735.1
Volume
75,741
Delivery %
51.0%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Nephrocare Health Services, upgrading to 'buy' from 'add' with a raised target price of ₹825 (from ₹725), val…” | ICICI Securities AnalysisICICI Securities | Nephrocare Health Services | PENDING |
Fundamentals
About Nephrocare Health Services Limited
Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Rohit Singh
Headquarters
Hyderabad
Employees
2,294
Website
nephroplus.comExchange
View on NSE ↗Key stats
Market cap
₹7,475.05 Cr
P/E ratio (TTM)
88.0
EPS (TTM)
₹8.45
Beta (1Y · daily vs NIFTY 50)
0.69
Shares float
2.84 Cr
EPS · quarter ended Jun 2026
₹3.11
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹414.53 Cr | ₹539.55 Cr | ₹748.34 Cr | ₹998.85 Cr | |
| EBITDA | ₹52.87 Cr | ₹107.05 Cr | ₹178.77 Cr | ₹244.93 Cr |
| ₹-11.79 Cr | ₹35.13 Cr | ₹67.10 Cr | ₹76.84 Cr | |
| Diluted EPS | ₹-1.17 | ₹3.5 | ₹6.69 | ₹8.1 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹666.23 Cr | ₹806.02 Cr | ₹996.46 Cr | ₹1,470.87 Cr | |
| ₹213.73 Cr | ₹267.84 Cr | ₹257.78 Cr | ₹79.71 Cr | |
| Stockholders' equity | ₹388.63 Cr | ₹413.71 Cr | ₹584.11 Cr | ₹1,116.49 Cr |
CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹11.27 Cr | ₹72.28 Cr | ₹135.35 Cr | ₹232.58 Cr | |
| Investing cash flow | — | ₹-78.21 Cr | ₹-50.66 Cr | ₹-125.07 Cr | ₹-410.44 Cr |
| — | ₹59.97 Cr | ₹26.74 Cr | ₹54.37 Cr | ₹157.11 Cr | |
| Capital expenditure | — | ₹-73.74 Cr | ₹-80.00 Cr | ₹-100.80 Cr | ₹-119.36 Cr |
| End cash position | — | ₹14.06 Cr | ₹61.15 Cr | ₹125.82 Cr | ₹123.89 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 25–Jun 26(4Q) |
|---|---|
| Promoter | 63.85% |
| Public | 36.15% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Nephrocare Health Services Limited | ₹7,393.10 Cr | ₹735.1 | 87.0 | 6.62 | 6.9% | 0.07 | +32.9% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Nephrocare Health Services secures acquisition in the Philippines worth PhP 67,200,000
Nephrocare Health Services Limited, through its Philippine subsidiary, acquired assets of a dialysis center from Renal One Dialysis Corp. for PhP 67.2 million. This acquisition expands Nephrocare's international presence and service offerings in the Southeast Asian healthcare market. The transaction is part of the company's strategic growth efforts.
'Buy' Nephrocare Health Services for 16% upside, says ICICI Securities; check share price target
TradingView · 8 days ago